What are the indications, contraindications, peri‑operative care, and alternative treatments for Aquaablation in men with symptomatic benign prostatic hyperplasia?

Aquablation for BPH

Aquablation should be offered to men with moderate-to-severe lower urinary tract symptoms (LUTS) and prostate volumes of 30-80 mL as an alternative to TURP, with particular consideration for sexually active men who prioritize preservation of ejaculatory function. 1

Indications

The 2023 European Association of Urology guidelines provide a weak recommendation to offer aquablation to patients with:

• Moderate-to-severe LUTS
• Prostate volume 30-80 mL
• Desire for an alternative to TURP 1

The 2020 AUA guidelines specify that eligibility requires prostate volume >30 mL and <80 mL 2. However, emerging evidence from 2025-2026 demonstrates that aquablation can be safely extended to larger prostates (80-150 mL), though with higher retreatment rates compared to simple prostatectomy 3, 4.

Key patient selection criteria:

• Men prioritizing ejaculatory preservation (87% maintain antegrade ejaculation at 3 years vs. 36% with TURP) 5, 6
• Patients on anticoagulation (aquablation can be performed safely) 7
• Men with indwelling catheters or urinary retention 7
• Patients with concomitant low-grade prostate cancer on active surveillance 8

Contraindications

While not explicitly stated in guidelines, relative contraindications include:

• Inability to tolerate general or spinal anesthesia
• Active urinary tract infection (should be treated first)
• Bleeding diathesis that cannot be corrected (though anticoagulation itself is not a contraindication)

Important caveat: The EAU guidelines mandate that clinicians must inform patients about the risk of bleeding and lack of long-term follow-up data (strong recommendation) 1.

Perioperative Care

Preoperative Assessment

• Document baseline IPSS, quality of life scores, maximum flow rate (Qmax), and post-void residual
• Assess ejaculatory function in sexually active men
• Measure prostate volume via ultrasound or MRI
• Check hemoglobin baseline (expect mean drop of 2.06 g/dL) 1

Operative Considerations

Operative time: 40-56 minutes median 7, 6, 4

Catheterization: Typically 48 hours 6

Hospital stay: 48 hours median, shorter than simple prostatectomy but comparable to TURP 3, 6

Postoperative Management

Bleeding management is critical: Early experience showed hemorrhage rates of 8.3%, but systematic cautery loop hemostasis techniques have reduced this to 1.4% 9. The learning curve matters—complication rates decline significantly after the first 30 cases 7.

Expected outcomes at 1 year:

• IPSS improvement: 14-19 points 7, 5
• Qmax improvement: to 18 mL/s 6
• Ejaculatory preservation: 82-87% 7, 6
• No de novo urinary incontinence 6

Complications: Most are Clavien-Dindo grade I-II (20-26%). High-grade complications (CD III-IV) occur in 2.7-4.3%, comparable to TURP 7, 6, 4. Common minor complications include hematuria, dysuria, urgency, and transient UTIs 1.

Retreatment rates: 4.3% surgical retreatment at mid-term follow-up (vs. 1.5% for TURP), with 5% requiring temporary medical retreatment at 3 years 1, 6. For prostates >80 mL, aquablation has higher retreatment rates than simple prostatectomy 3.

Alternative Treatments

Standard Surgical Options (30-80 mL prostates)

TURP (bipolar or monopolar): Remains the gold standard with a strong recommendation 1. Provides superior retreatment rates (1.5% vs. 4.3%) but higher ejaculatory dysfunction (36-64% vs. 10-13% with aquablation) 1, 5.

Laser enucleation (HoLEP, ThuLEP): Strong recommendation as alternative to TURP or open prostatectomy 1. HoLEP provides higher flow rates than aquablation but only 18% ejaculatory preservation 7.

GreenLight PVP (180-W): Strong recommendation for 30-80 mL prostates 1. Comparable efficacy to TURP with shorter catheterization time but similar ejaculatory dysfunction rates (50-57%) 1.

Prostatic urethral lift (Urolift): Strong recommendation for men with prostate <70 mL, no middle lobe, who desire ejaculatory preservation 1. However, symptom improvement is inferior to TURP at 24 months with 13.6% retreatment rate at 5 years 1.

For Larger Prostates (>80 mL)

Simple prostatectomy (open/robotic): Strong recommendation when HoLEP/bipolar enucleation unavailable 1. For prostates >80 mL, simple prostatectomy provides better 1-year IPSS scores and lower retreatment rates than aquablation, but requires longer operative time (119 minutes longer), hospital stay (1.7 days longer), and has higher transfusion rates 3.

HoLEP: Strong recommendation as alternative to open prostatectomy for large prostates 1.

Minimally Invasive Options

Water vapor thermal therapy (Rezūm): May be offered for prostates <80 mL with preservation of erectile and ejaculatory function (conditional recommendation) 2.

Prostatic artery embolization (PAE): Weak recommendation for men accepting less optimal outcomes than TURP, performed only in specialized centers 1. Inferior symptom improvement and urodynamic parameters compared to TURP 1.

Key Clinical Pearls

• Aquablation's primary advantage is ejaculatory preservation (82-87% vs. 18-36% with other surgical options), making it ideal for sexually active men 7, 5, 6
• The procedure has a shorter learning curve than HoLEP due to semi-automated technology 10, 7
• Bleeding risk is the main concern—ensure proper training in cautery loop hemostasis techniques 9
• For prostates >80 mL, counsel patients about higher retreatment rates compared to simple prostatectomy 3
• Cost remains a barrier to widespread adoption 10
• Emerging data suggests aquablation may reduce pathologic upgrading in men on active surveillance for prostate cancer (44% fewer events, HR 0.48) 8